Reservoirs of human immunodeficiency virus type 1: The main obstacles to viral eradication

Clinical Infectious Diseases

Volumn 34, Issue 1, 2002, Pages 91-97

  Pomerantz, R J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; DEVELOPED COUNTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; REMISSION; T LYMPHOCYTE; VIRUS CARRIER; VIRUS DETECTION; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARRIER STATE; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS, FOLLICULAR; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0036133364     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/338256     Document Type: Article

References (52)

1. AIDS and other diseases due to HIV infection
2. Prognosis in HIV infection predicted by the quantity of virus in plasma
3. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
4. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection
7. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
8. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
9. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection
10. Decay characteristics of HIV-1-infected compartments during combination therapy
11. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
12. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
13. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy
14. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy
15. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1
16. + T cells during primary HIV-1 infection
17. + T-cells using a combination of cytokines
18. + T-lymphocytes in infected children
19. Generation of HIV latency during thympoiesis
20. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent anti-retroviral therapy
21. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals
22. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy
23. + T-cell depletion and viral replication in SIV infection
24. Infection of the retina by human immunodeficiency virus type 1
25. HIV-1 in the semen of men receiving highly active anti-retroviral therapy
26. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years
27. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
28. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
29. Poor penetration of the male genital tract by HIV-1 protease inhibitors
30. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen
31. Effect of antiretroviral therapy on HIV shedding in semen
32. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA
33. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
34. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
35. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
36. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
37. Human immunodeficiency virus type 1-infected persons with residual disease and viral reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups
38. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency
39. + T cells
40. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
41. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
42. Genetic characterization of rebounding HIV-1 after cessation of highly active anti-retroviral therapy
43. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active anti-retroviral therapy (HAART)
44. + T-cells provides a mechanism for lifelong persistence of HIV-1 even inpatients on effective combination therapy
45. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
46. Prevalence and predictive value of intermittent viremia with combination HIV therapy
47. The significance of low-level viremia in patients with previously "undetectable" HIV-1 RNA levels
48. The natural history and clinical significance of intermittent virological "blips" in patients who attain an initially undetectable viral load (VL) on HAART
49. Dissociation of HIV-1 from follicular dendritic cells during HAART: Mathematical analysis
50. Residual HIV-1 infection during antiretroviral therapy: The challenge of viral persistence
51. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART